Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Outlook Therapeutics (OTLK) Long-Term Debt Repayments (2016 - 2025)

Outlook Therapeutics (OTLK) has disclosed Long-Term Debt Repayments for 6 consecutive years, with $2.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Long-Term Debt Repayments changed N/A to $2.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $36.1 million, a N/A change, with the full-year FY2025 number at $36.1 million, changed N/A from a year prior.
  • Long-Term Debt Repayments was $2.3 million for Q3 2025 at Outlook Therapeutics, up from $906977.0 in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $32.9 million in Q1 2025 to a low of $906977.0 in Q2 2025.